Trastuzumab Biosimilar Equivalent in Early HER2+ Breast CA Tx (CME/CE)

(MedPage Today) -- Ratio of breast pathologic complete response rate 10% higher with SB3
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news